Chronic kidney disease, preoperative use of antispasmodics and lower resected prostate volume ratios are risk factors for postoperative use of adrenergic Alpha-blockers and antispasmodics

• Published in: PloS one 2023-03, Vol.18 (3), p.e0282745-e0282745
• Main Authors: Hsueh, Chen-Hsun, Chang, Li-Wen, Chiu, Kun-Yuan, Hung, Sheng-Chun, Chen, Jun-Peng, Li, Jian-Ri
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-Antagonists - therapeutic use; Adrenergic receptors; Antigens; Antispasmodics; Biology and Life Sciences; Biopsy; Bladder; Body mass; Body mass index; Body size; Cancer surgery; Cancer therapies; Care and treatment; Chronic kidney failure; Chronic obstructive pulmonary disease; Comorbidity; Complications and side effects; Diagnosis; Engineering and Technology; Humans; Hyperplasia; Hypertension; Hypertrophy; Kidney diseases; Kidneys; Lasers; Male; Medicine and Health Sciences; Multivariate analysis; Parasympatholytics; Patient outcomes; Patients; Prostate; Prostate - surgery; Prostate cancer; Prostatectomy; Prostatic Hyperplasia - complications; Prostatic Hyperplasia - drug therapy; Prostatic Hyperplasia - surgery; Ratios; Reductases; Retrospective Studies; Risk Factors; Smooth muscle; Spinal cord injuries; Surgery; Transurethral Resection of Prostate - methods; Treatment Outcome; Urological surgery
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0282745

Transurethral resection of prostate (TURP) and laser prostate surgery are common surgeries for benign prostate hyperplasia (BPH). We conducted an investigation using hospital database to evaluate the clinical factors associated with post-operative usage of alpha-blockers and antispasmodics. This study was conducted using retrospective clinical data from the hospital database, which contained newly diagnosed BPH patients between January 2007 and December 2012 who subsequently received prostate surgery. The study end-point was the use of alpha-blockers or antispasmodics for at least 3 months duration after 1 month of surgery. The exclusion criteria was prostate cancer diagnosed before or after the surgery, recent transurethral surgeries, history of open prostatectomy, and history of spinal cord injury. Clinical parameters, including age, body mass index, preoperative prostate specific antigen value, comorbidities, preoperative usage of alpha-blockers, anstispasmodics and 5-alpha reductase inhibitors, surgical methods, resected prostate volume ratios, and preoperative urine flow test results, were evaluated. A total of 250 patients receiving prostate surgery in the database and confirmed pathologically benign were included. There was significant association between chronic kidney disease (CKD) and the usage of alpha-blockers after prostate surgery (OR = 1.93, 95% CI 1.04-3.56, p = 0.036). Postoperative antispasmodics usage was significantly associated with preoperative usage of antispasmodics (OR = 2.33, 95% CI 1.02-5.36, p = 0.046) and resected prostate volume ratio (OR = 0.12, 95% CI 0.02-0.63, p = 0.013). BPH patients with underlying CKD were more likely to require alpha-blockers after surgery. In the meantime, BPH patients who required antispasmodics before surgery and who received lower prostate volume resection ratio were more liable to antispasmodics after prostate surgery.